THTX
Well who could see more than 50 percent depreciation because of an protocol amendment? As some have mentioned lack of demand/illiquidity can cause this panic selling almost cost half of the valuation.
But they have two commercial drugs which is generating revenues and have growth potentials specifically Tesamorelin. The issue is the market/investors want to see the sale growth Q after Q! a sustained increase of sales which by the looks of recent price action Mr market has totally ignored that aspect/value/opportunity of their business.
With or without oncology the selling and lack of demand for the stocks is not justified having said that that radio silence hasn’t been helpful at all for a company who has to rebuild their credibility. I recall many here many were suggesting getting ride of the commercial products and only relying on the high risk high reward R&D operations I guess those folks now realize that is even riskier strategy. I personally want this company to be more transparent for all their operation less guesswork more clarity!
“Our current data demonstrate that tesamorelin iseffective at reducing VAT in patients regardless of dorsocervical fat deposition. Indeed, the presence of dorsocervical fat was associated with very few differences in central anthropometricmeasurements. Interestingly, only responders without dorsocervical fat had additional reductions in SAT and limb fat at week 26 which may be due to baseline differences in fat burden, or could reflect differences in adipose function in individuals with dorsocervical fat.16,17 Metabolic measurements were similarly equivalent between those with and without dorsocervical fat. While there were some differences in HIV- related parameters, these did not consistently differ by dorsocervical status at baseline and week 26. Furthermore neither CD4 count nor viral load has been previously shown to differ by tesamorelin response.14 This has important clinical implications as tesamorelin is the only FDA approved treatment for reduction of VAT and data was lacking as to whether persons who also had excessive dorsocervical fat would still benefit from its use in VAT reduction.”
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/A85B89546C8B7C2B04307E4BB8B69270/S2059866122005155a.pdf/effect_of_tesamorelin_in_people_with_hiv_with_and_without_dorsocervical_fat_post_hoc_analysis_of_phase_iii_double_blind_placebo_control_trial.pdf